As of 2025-04-22, the Relative Valuation of Citius Pharmaceuticals Inc (CTXR) is (57.65) USD. This relative valuation is based on P/E multiples. With the latest stock price at 0.86 USD, the upside of Citius Pharmaceuticals Inc based on Relative Valuation is -6803.3%.
The range of the Relative Valuation is (51.12) - (69.01) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 12.1x - 16.3x | 14.0x |
| Forward P/E multiples | 10.4x - 16.5x | 13.2x |
| Fair Price | (51.12) - (69.01) | (57.65) |
| Upside | -6044.3% - -8124.3% | -6803.3% |
| Date | P/E |
| 2025-04-21 | -0.22 |
| 2025-04-17 | -0.23 |
| 2025-04-16 | -0.23 |
| 2025-04-15 | -0.24 |
| 2025-04-14 | -0.23 |
| 2025-04-11 | -0.22 |
| 2025-04-10 | -0.23 |
| 2025-04-09 | -0.25 |
| 2025-04-08 | -0.23 |
| 2025-04-07 | -0.25 |
| 2025-04-04 | -0.24 |
| 2025-04-03 | -0.24 |
| 2025-04-02 | -0.28 |
| 2025-04-01 | -0.28 |
| 2025-03-31 | -0.35 |
| 2025-03-28 | -0.37 |
| 2025-03-27 | -0.31 |
| 2025-03-26 | -0.32 |
| 2025-03-25 | -0.35 |
| 2025-03-24 | -0.37 |
| 2025-03-21 | -0.36 |
| 2025-03-20 | -0.37 |
| 2025-03-19 | -0.38 |
| 2025-03-18 | -0.39 |
| 2025-03-17 | -0.36 |
| 2025-03-14 | -0.35 |
| 2025-03-13 | -0.37 |
| 2025-03-12 | -0.38 |
| 2025-03-11 | -0.38 |
| 2025-03-10 | -0.37 |
| 2025-03-07 | -0.42 |
| 2025-03-06 | -0.42 |
| 2025-03-05 | -0.40 |
| 2025-03-04 | -0.38 |
| 2025-03-03 | -0.37 |
| 2025-02-28 | -0.39 |
| 2025-02-27 | -0.39 |
| 2025-02-26 | -0.39 |
| 2025-02-25 | -0.40 |
| 2025-02-24 | -0.40 |
| 2025-02-21 | -0.42 |
| 2025-02-20 | -0.44 |
| 2025-02-19 | -0.51 |
| 2025-02-18 | -0.58 |
| 2025-02-14 | -0.63 |
| 2025-02-13 | -0.64 |
| 2025-02-12 | -0.62 |
| 2025-02-11 | -0.62 |
| 2025-02-10 | -0.64 |
| 2025-02-07 | -0.63 |